etoposide + paclitaxel + pegylated liposomal doxorubicin

This is a combination chemotherapy regimen consisting of three agents: - **Etoposide** (a topoisomerase II inhibitor), - **Paclitaxel** (a taxane that stabilizes microtubules and inhibits cell division), and - **Pegylated liposomal doxorubicin** (an anthracycline antibiotic formulated in PEG-coated liposomes to improve pharmacokinetics and reduce toxicity). Each drug has a distinct mechanism of action targeting cancer cells at different points in the cell cycle. Etoposide induces DNA strand breaks by inhibiting topoisomerase II, leading to apoptosis. Paclitaxel promotes microtubule assembly and prevents their disassembly, causing mitotic arrest. Pegylated liposomal doxorubicin intercalates into DNA, inhibits topoisomerase II, and generates free radicals that damage cellular components; its pegylation allows for prolonged circulation time and reduced cardiotoxicity compared to conventional doxorubicin. This combination is not a standard named regimen but may be used experimentally or off-label for certain cancers where multi-agent chemotherapy is indicated—most commonly in breast cancer or other solid tumors when aggressive treatment is warranted[1][2][3]. The sequence of administration can affect efficacy and toxicity due to potential antagonism between these agents[1][2].